An engineered cyclic peptide alleviates symptoms of inflammation in a murine model of inflammatory bowel disease.

ABSTRACT: Inflammatory bowel diseases (IBDs) are a set of complex and debilitating diseases for which there is no satisfactory treatment. Recent studies have shown that small peptides show promise for reducing inflammation in models of IBD. However, these small peptides are likely to be unstable and rapidly cleared from the circulation, and therefore, if not modified for better stability, represent non-viable drug leads. We hypothesized that improving the stability of these peptides by grafting them into a stable cyclic peptide scaffold may enhance their therapeutic potential. Using this approach, we have designed a novel cyclic peptide that comprises a small bioactive peptide from the annexin A1 protein grafted into a sunflower trypsin inhibitor cyclic scaffold. We used native chemical ligation to

SUBMITTER: Cobos Caceres C 

PROVIDER: S-EPMC5473231 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature